| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1af810e7a75c5bfe6754e84b506fd46f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20071 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cb575591f94ec4844af10cef326518e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b6b81660d4aff1ced084c4fb1ae784d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6df65de4a0a6eb16cc6818083709a5c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e325c974af3c0e7e84dafe3c588f9a98 |
| publicationDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2021200200-A1 |
| titleOfInvention |
Novel HPV16 non HLA-restricted T-cell vaccines, compositions and methods of use thereof |
| abstract |
Novel human papillomovirus immunogenic compositions and methods of use thereof are nprovided. The compositions comprise unique combinations ofmulti-epitope peptide sequences nspecifically selected and designed to be effectively processed and cross-presented to T-cells. nThe peptides utilized in the compositions display high levels of binding with HLA-supertypes. nThe immunogenic compositions are broadly applicable to large proportions of target npopulations. The compositions comprise adjuvants such as cationic lipids. |
| priorityDate |
2016-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |